Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.42 |
| ▸ | HTT | P42858 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MMP14 | P50281 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30351059 | 1.00 | KDM4E (0.42) | KDM4EHTTSMN1; SMN2TDP1HSP90AA1 | |
| SCHEMBL30351236 | 0.81 | MAPT (0.44) | KDM4EHTTSMN1; SMN2TDP1HSP90AA1 | |
| SCHEMBL11007450 | 0.81 | MAPT (0.44) | KDM4EHTTSMN1; SMN2TDP1HSP90AA1 | |
| SCHEMBL2171980 | 0.79 | HTT (0.40) | KDM4EHTTSMN1; SMN2TDP1HSP90AA1 | |
| SCHEMBL30351110 | 0.79 | KDM4E (0.43) | KDM4EHTTSMN1; SMN2TDP1HSP90AA1 | |
| SCHEMBL25229833 | 0.79 | KDM4E (0.43) | KDM4EHTTSMN1; SMN2TDP1HSP90AA1 | |
| SCHEMBL2171979 | 0.79 | HTT (0.40) | KDM4EHTTSMN1; SMN2TDP1HSP90AA1 | |
| SCHEMBL29924149 | 0.76 | NOS3 (0.41) | KDM4EHTTSMN1; SMN2TDP1HSP90AA1 | |
| SCHEMBL24916103 | 0.76 | NOS3 (0.41) | KDM4EHTTSMN1; SMN2TDP1HSP90AA1 | |
| SCHEMBL25210212 | 0.75 | MEN1 (0.36) | KDM4EHTTSMN1; SMN2TDP1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-23 | — | — | US | disclosed |
| EP-4423081-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118201920-A | PAPD5 inhibitors and methods of use thereof | 儿童医疗中心公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023086220-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-3124482-B1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-09-11 | — | — | EP | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| EP-3124482-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | KDM4E 2544/4885HTT 481/4885SMN1; SMN2 2880/4885 |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | KDM4E 415/4885HTT 1275/4885SMN1; SMN2 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.